Turnstone Biologics Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$9.6M
- Investors
-
1
Turnstone Biologics General Information
Description
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Contact Information
Website
www.turnstonebio.comCorporate Office
- 9310 Athena Circle
- Suite 300
- La Jolla, CA 92037
- United States
Corporate Office
- 9310 Athena Circle
- Suite 300
- La Jolla, CA 92037
- United States
Turnstone Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 11-Aug-2025 | $9.6M | Completed | Generating Revenue | ||
| 8. IPO | 21-Jul-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 14-Jul-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 19-Dec-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | 04-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series B) | 02-Nov-2016 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 28-Oct-2015 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 04-May-2015 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2014 | Completed | Pre-Clinical Trials |
Turnstone Biologics Comparisons
Industry
Financing
Details
Turnstone Biologics Competitors (60)
One of Turnstone Biologics’s 60 competitors is TScan Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Vyriad | Venture Capital-Backed | Rochester, MN | ||||
| Instil Bio | Formerly VC-backed | Dallas, TX | ||||
| Dendreon | Formerly VC-backed | Seal Beach, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Turnstone Biologics Patents
Turnstone Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025096638-A2 | Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same | Inactive | 30-Oct-2023 | ||
| WO-2025096638-A3 | Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same | Inactive | 30-Oct-2023 | ||
| WO-2025080865-A1 | Combination of tumor infiltrating lymphocytes (til) and low dose radiation | Inactive | 11-Oct-2023 | ||
| WO-2024192051-A1 | Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same | Inactive | 13-Mar-2023 | ||
| US-20260199414-A1 | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors | Pending | 16-Dec-2022 | A61K35/76 |
Turnstone Biologics Signals
Turnstone Biologics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brace Pharma Capital | Corporate Venture Capital | Minority | ||
| CaaS Capital Management | Hedge Fund | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| Eventide Asset Management | Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority |
Turnstone Biologics Acquisitions (1)
Turnstone Biologics’s most recent deal was a Merger/Acquisition with Myst Therapeutics. The deal was made on 20-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Myst Therapeutics | 20-Jan-2021 | Merger/Acquisition | Biotechnology |
Turnstone Biologics ESG
Risk Overview
Risk Rating
Updated October, 31, 2025
33.82 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Turnstone Biologics FAQs
-
When was Turnstone Biologics founded?
Turnstone Biologics was founded in 2014.
-
Where is Turnstone Biologics headquartered?
Turnstone Biologics is headquartered in La Jolla, CA.
-
What is the size of Turnstone Biologics?
Turnstone Biologics has 3 total employees.
-
What industry is Turnstone Biologics in?
Turnstone Biologics’s primary industry is Biotechnology.
-
Is Turnstone Biologics a private or public company?
Turnstone Biologics is a Private company.
-
What is the current valuation of Turnstone Biologics?
The current valuation of Turnstone Biologics is .
-
What is Turnstone Biologics’s current revenue?
The current revenue for Turnstone Biologics is .
-
How much funding has Turnstone Biologics raised over time?
Turnstone Biologics has raised $375M.
-
Who are Turnstone Biologics’s investors?
Brace Pharma Capital, CaaS Capital Management, Eight Roads, Eventide Asset Management, and F-Prime are 5 of 19 investors who have invested in Turnstone Biologics.
-
Who are Turnstone Biologics’s competitors?
TScan Therapeutics, Vyriad, Instil Bio, Dendreon, and Kite Pharma are some of the 60 competitors of Turnstone Biologics.
-
When was Turnstone Biologics acquired?
Turnstone Biologics was acquired on 11-Aug-2025.
-
Who acquired Turnstone Biologics?
Turnstone Biologics was acquired by Xoma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process